

## Xofluza® (baloxavir marboxil) - Expanded indication

- On March 1, 2024, the <u>FDA approved</u> Genentech's <u>Xofluza (baloxavir marboxil)</u>, for treatment of
  acute uncomplicated influenza in patients 5 years of age and older who have been symptomatic
  for no more than 48 hours and who are otherwise healthy or at high risk of developing influenzarelated complications.
  - This approval expands the patient population to include the treatment of pediatric patients between the ages of 5 to < 12 years old with acute uncomplicated influenza who are at high risk of developing influenza-related complications.
- Xofluza is also approved for post-exposure prophylaxis of influenza in persons 5 years of age and older following contact with an individual who has influenza.
- The most common adverse reactions (at least 5%) with Xofluza use in pediatric patients between the ages of 5 and < 12 years old were vomiting and diarrhea.</li>
- Refer to the Xofluza drug label for complete dosing and administration recommendations for both the tablet and oral suspension formulations.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.